Is the Thomas Cook share price a buy after 20% jump?

The Thomas Cook Group plc (LON: TCG) share price climbs in response to radical plans to turn the travel giant around.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I recently took a look at the big share price fall at Thomas Cook Group (LSE: TCG) following on from its dreadful interim results a few days earlier.

There are fears that, in the light of the company’s troubles, potential customers will stay away and that this could create a further downwards spiral.

But after losing more than 90% of their value in 12 months, Thomas Cook shares leapt 20% on Tuesday morning. There’s little concrete news, but there is a lot of speculation over the firm’s recovery direction after meetings with major investors before the bank holiday.

Online

While a move to farm out its aviation services to other airlines once the sale of Thomas Cook Airlines completes is clearly on the cards, there are big hints the firm will move to become more of an online marketplace. After all, about the only upbeat thing to come from those first-half results was the increasing number of customers booking online.

The company is still expected to maintain its chain of hotels, but the sale of other assets (including the airline) should raise significant cash to help with that massive net debt (which stood at £1,247m at 31 March). We’ve had confirmation of interest in both its airline and its Northern Europe business.

Thomas Cook shares are still on a P/E rating of only around four, and that looks like it’s priced to go bust. I’m fairly confident that Thomas Cook will survive, but I have fears over how much will be left for current shareholders once the balance sheet has been shored up. I’m still steering clear.

Another climber

The other big winner that has caught my eye Tuesday is Oxford Biomedica (LSE: OXB), whose shares are up 10% on the day as I write.

I’ve had my eye on it for some time. The gene and cell therapy researcher finally turned in a profit in 2018, and this year investors have been cautiously pushing up the share price. We’re looking at a 16% gain since the end of 2018, though admittedly that’s mostly been due to this one-day rise.

The driver of the price spike appears to be an agreement by Novo Holdings to invest up to £53.5m in Oxford Biomedica, with an issue of new shares amounting to around 10% of the enlarged company.

Cash relief

As well as going partly towards the further development of the firm’s LentiVector gene and cell therapy platform and its product portfolio, the cash will also enable Oxford to “repay the existing debt facility with Oaktree Capital Management in full.”

A couple of years ago, the business looked like a cash-burn, blue-sky prospect, albeit one with promising prospects in a key new biotechnology market. Today, we’re looking at a profitable company with a soon-to-be solid balance sheet and much reduced risk.

The share price has trebled in those two years, but I can’t help feeling the risk to reward balance is more in investors’ favour right now and that the full potential is not reflected in the current share price.

We’re looking at a P/E multiple for 2020 of 30, which might look high. But that’s based on early profits, and I could see it coming down rapidly in the next few years. Oxford Biomedica is on my shortlist.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »